A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT01969357
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Registry
-
NCT01969357
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01969357. Randomized; quadruple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- 50 mg SP2086
- Intervention (Drug)
- 100 mg SP2086
- Intervention (Drug)
- 200 mg SP2086
- Intervention (Drug)
- 100 mg Sitagliptin
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct01969357- Content hash
231bc5c8cefc1b145cf2c2eeb9d1e15bc785c9077c52ef37b67f30e99887cfe0